Fate Therapeutics Financials
| FATE Stock | USD 0.91 0.03 3.19% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.52 | 7.5777 |
|
|
The financial analysis of Fate Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Fate Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Fate | Select Account or Indicator |
Understanding current and past Fate Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Fate Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Fate Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Fate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Fate Therapeutics' management manipulating its earnings.
Fate Therapeutics Stock Summary
Fate Therapeutics competes with Atara Biotherapeutics, Sana Biotechnology, Caribou Biosciences, Arcus Biosciences, and Intellia Therapeutics. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Fate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 542 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US31189P1021 |
| CUSIP | 31189P102 |
| Location | California; U.S.A |
| Business Address | 12278 Scripps Summit |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.fatetherapeutics.com |
| Phone | 858 875 1800 |
| Currency | USD - US Dollar |
Fate Therapeutics Key Financial Ratios
| Return On Equity | -0.54 | ||||
| Operating Margin | (25.27) % | ||||
| Price To Sales | 7.87 X | ||||
| Revenue | 13.63 M | ||||
| Gross Profit | (104.9 M) |
Fate Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 622.5M | 921.5M | 705.6M | 506.2M | 440.7M | 322.6M | |
| Other Current Liab | 51.4M | 40.0M | 52.3M | 27.5M | 21.3M | 18.1M | |
| Other Liab | 4.5M | 58.5M | 52.1M | 3.9M | 4.4M | 4.2M | |
| Net Debt | (70.0M) | (18.8M) | 48.0M | 61.7M | 49.2M | 51.7M | |
| Retained Earnings | (556.9M) | (769.1M) | (1.1B) | (1.2B) | (1.4B) | (1.3B) | |
| Accounts Payable | 6.3M | 8.6M | 8.3M | 4.7M | 9.4M | 9.8M | |
| Cash | 167.3M | 133.6M | 61.3M | 41.9M | 36.1M | 34.3M | |
| Other Assets | 95.8M | 25.1M | 22.5M | 1.0 | 1.15 | 1.09 | |
| Other Current Assets | 4.4M | 8.8M | 27.4M | 14.5M | 9.3M | 6.2M | |
| Total Liab | 238.0M | 242.6M | 221.6M | 137.8M | 122.0M | 102.3M | |
| Total Current Assets | 494.3M | 633.4M | 502.1M | 331.5M | 291.9M | 241.1M | |
| Short Term Debt | 6.7M | 11.2M | 11.3M | 6.2M | 7.4M | 6.0M | |
| Common Stock | 88K | 96K | 97K | 99K | 114K | 62.9K | |
| Net Tangible Assets | 274.5M | 536.9M | 678.8M | 483.9M | 556.5M | 584.4M | |
| Capital Surpluse | 445.8M | 628.2M | 941.2M | 1.4B | 1.7B | 1.7B | |
| Net Invested Capital | 384.4M | 678.8M | 483.9M | 368.4M | 318.7M | 377.6M |
Fate Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 1.8M | 2.4M | 4.5M | 5.8M | 6.7M | 7.1M | |
| Total Revenue | 31.4M | 55.8M | 96.3M | 63.5M | 13.6M | 22.9M | |
| Gross Profit | (94.2M) | 50.0M | 96.3M | (98.2M) | 13.6M | 14.3M | |
| Operating Income | (128.1M) | (217.0M) | (308.4M) | (190.5M) | (210.3M) | (199.8M) | |
| Ebit | (128.1M) | (217.0M) | (308.4M) | (190.5M) | (195.5M) | (185.8M) | |
| Research Development | 125.6M | 215.5M | 320.5M | 172.6M | 135.0M | 97.7M | |
| Ebitda | (125.0M) | (211.1M) | (294.6M) | (172.2M) | (176.6M) | (167.7M) | |
| Cost Of Revenue | 125.6M | 5.9M | 13.8M | 161.7M | 186.0M | 195.2M | |
| Income Before Tax | (173.4M) | (212.2M) | (281.7M) | (160.9M) | (186.3M) | (176.9M) | |
| Net Income | (170.3M) | (206.3M) | (255.1M) | (160.9M) | (186.3M) | (176.9M) | |
| Income Tax Expense | (3.1M) | (5.9M) | (26.7M) | 18.1M | 16.3M | 17.1M | |
| Interest Income | 2.4M | 1.3M | 5.8M | 15.7M | 17.3M | 18.2M | |
| Net Interest Income | 2.4M | 1.3M | 5.8M | 15.7M | 17.3M | 18.2M |
Fate Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 82.5M | (33.8M) | (72.3M) | (19.5M) | (10.8M) | (10.2M) | |
| Free Cash Flow | (44.2M) | (213.6M) | (283.8M) | (138.4M) | (123.6M) | (129.8M) | |
| Depreciation | 3.1M | 5.9M | 13.8M | 18.3M | 9.9M | 10.4M | |
| Other Non Cash Items | 111.4M | (18.1M) | (24.3M) | (52.3M) | 12.0M | 12.6M | |
| Capital Expenditures | 4.9M | 50.7M | 35.6M | 6.2M | 730K | 693.5K | |
| Net Income | (173.4M) | (212.2M) | (281.7M) | (160.9M) | (186.3M) | (176.9M) | |
| End Period Cash Flow | 182.6M | 148.8M | 76.6M | 57.0M | 46.3M | 91.4M | |
| Change To Inventory | (4.3M) | (4.3M) | 1.6M | (5.9M) | (5.3M) | (5.1M) | |
| Change To Netincome | 17.4M | 30.8M | 37.3M | 51.8M | 59.6M | 62.5M | |
| Investments | (156.1M) | (273.3M) | 166.8M | 120.4M | 12.2M | 12.8M |
Fate Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fate Therapeutics's current stock value. Our valuation model uses many indicators to compare Fate Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fate Therapeutics competition to find correlations between indicators driving Fate Therapeutics's intrinsic value. More Info.Fate Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Fate Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Fate Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Fate Therapeutics Systematic Risk
Fate Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Fate Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Fate Therapeutics correlated with the market. If Beta is less than 0 Fate Therapeutics generally moves in the opposite direction as compared to the market. If Fate Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Fate Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Fate Therapeutics is generally in the same direction as the market. If Beta > 1 Fate Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Fate Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Fate Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Fate Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Fate Therapeutics March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Fate Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Fate Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Fate Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Fate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Fate Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 22.21 | |||
| Value At Risk | (9.56) | |||
| Potential Upside | 9.29 |
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |